BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 17722077)

  • 21. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.
    Hoogendoorn M; Olde Wolbers J; Smit WM; Schaafsma MR; Jedema I; Barge RM; Willemze R; Falkenburg JH
    Clin Cancer Res; 2005 Jul; 11(14):5310-8. PubMed ID: 16033850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mantle cell lymphoma in the ocular adnexal region.
    Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
    Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
    Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of mantle cell lymphoma: targeting the microenvironment.
    Drach J; Seidl S; Kaufmann H
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
    Seggewiss R; Ho AD; Kraemer A
    Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M; Schechter GP
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mantle cell lymphoma: advances in biology and therapy.
    Smith MR
    Curr Opin Hematol; 2008 Jul; 15(4):415-21. PubMed ID: 18536582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in immunotherapy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Ruan J; Coleman M
    Curr Oncol Rep; 2005 Sep; 7(5):364-71. PubMed ID: 16091197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.
    Zwick C; Preuss KD; Kubuschok B; Held G; Ahlgrimm M; Bittenbring J; Schubert J; Neumann F; Pfreundschuh M
    Ann Hematol; 2009 Oct; 88(10):999-1003. PubMed ID: 19238384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.